📢 Save the date! 3rd European Purine Meeting
🗓️ 1–3 July 2026 |
📍 Bordeaux, France (Univ. Bordeaux, Campus Victoire)
Preceded by the final PRESTO meeting: 30 June–1 July 2026
🌐 Call for Symposia now open: live.eventtia.com/en/european-...
#P1 #P2X#P2Y #ATP #adenosine #purinergic #signalling
Our PhD student, Johanna Augros, represented our lab exceptionally well at the International Society on Thrombosis and Haemostasis @isth.org meeting that took place in Washington. See you next year at the ISTH next meeting in Paris!
Members of INSERM UMR1327 Ischemia: Mohammed ELMALLAH, Marylou PICHONNIERE and Oumnia BENOUNA were pleased to present their work yesterday, at the Annual meeting of the @frenchpurine.bsky.social in Paris. A meeting enriched by relevant scientific discussions.
We thank the organizers of the PRESTO COST action meeting (Dublin, Ireland, 22-24/05), on the topic "Purinergic signalling: from bench-to-bedside, where are we now?"
Congratulations to our unit members W. ECHCHIH, M. PICHONNIERE, M. ElMALLAH, A. HERAUD-MELEY and O. BENOUNA for their presentations.
Synthèse sur "Les anticorps monoclonaux dans les maladies immuno-inflammatoires" dans le dernier N° de La Lettre du Pharmacologue, consacré à la pharmacologie de l'inflammation
par G. Paintaud, O. Le Tilly, D. Ternant, C. Desvignes et @theodorabejan.bsky.social
www.edimark.fr/revues/la-le...
Yesterday, Oumnia Benouna, Ana Valéria Vinhais da Silva, Johanna Augros, Marylou Pichonnière, Claire Hosemans and Wiam Echchih (UMR1327), participated to a 10 km "Parcours du cœur" at Bergeonnerie Lake (Tours), a walk dedicated to raising awareness about heart health.
Thanks to the organizers!
Nous avons le plaisir de participer au programme "Ma thèse en BD" de l'université de Tours.
Les planches 2024-2025, réalisées par 3 dessinatrices/teurs avec 5 doctorant.es, sont téléchargeables et feront l'objet de plusieurs expos, notamment lors du festival 2025
saps.univ-tours.fr/decouvrez-le...
Credibility assessment of a mechanistic model of atherosclerosis to predict cardiovascular outcomes under lipid-lowering therapy
Denis Angoulvant @dangoulvant.bsky.social is coauthor of this paper by Yishu Wang et al., published in NPJ Digit Med
rdcu.be/ehav0
Prognosis of patients with acute myocardial infarction in the setting of COVID-19: A French nationwide observational study
by Ahmad Abou Hamed, Maeva Gourraud, Thibaud Genet, François Barbier, Denis Angoulvant, Laurent Fauchier and Fabrice Ivanes
www.sciencedirect.com/science/arti...
Conférences Sport & Santé
le 21 mars à MAME (Tours) à 17h30
Un événement organisé par Tours Autogreffe
Nous sommes à la recherche de candidat.es pour notre poste d'Assistant Hospitalo-universitaire, qui sera disponible en novembre 2025.
Contacts : Theodora Bejan-Angoulvant @theodorabejan.bsky.social ou David Ternant
Merci de reposter !
Cardiovascular risk associated with glucagon-like peptide-1 receptor agonists versus other conventional glucose-lowering drugs in patients with type-2 diabetes:
protocol for a nationwide observational comparative study in routine care
bmjopen.bmj.com/content/15/1...
Publication of the PHARBEVACOL study protocol:
Bevacizumab-based chemotherapy adaptive to PK of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study
www.sciencedirect.com/science/arti...
Bonjour, une action est signalée à Tours : standupforscience.fr/tous-les-eve... 👍
Outcomes in Atrial Fibrillation Patients with Different Clinical Phenotypes: Insights from the French Population
by A.M. Fawzy, A. Bisson, L. Lochon, T. Lenormand, G.Y.H. Lip and L. Fauchier
@liverpoolccs.bsky.social @chrudetours.bsky.social @chuorleans.bsky.social
www.mdpi.com/3171158
@dangoulvant.bsky.social is coauthor of
Quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial
www.sciencedirect.com/science/arti...
TMA from peptide receptor radionuclide therapy
P Delalande, M Bobot, M Essig, C Simon, AP Jonville-Béra, C Barbet, B Sautenet, V Maisons, T Carsuzaa, F Bruyère and JM Halimi
@aphm-chu-marseille.bsky.social @hopambroisepare.bsky.social @chrudetours.bsky.social
www.sciencedirect.com/science/arti...
Towards Personalized Prevention: The Role of ECG in Cardiovascular Risk Prediction for Type 2 Diabetes
in Eur J Prev Cardiol 2025
by A. Bisson and D. Angoulvant, Inserm UMR1327 and Departments of Cardiology of @chrudetours.bsky.social and @chuorleans.bsky.social
academic.oup.com/eurjpc/artic...
Imaging flow cytometry for the diagnosis of HIT
by Carré J, Demont Y, Mouton C, Vayne C, Guéry EA, Voyer A, Garçon L, Le Guyader M, Demagny J
@chuamiens.bsky.social @chu-bordeaux.fr @chrudetours.bsky.social
in Br J Haematol 2025 @bsochaem.bsky.social
onlinelibrary.wiley.com/doi/10.1111/...
Nous avons le plaisir de vous inviter aux 3ᵉ Journées Scientifiques du French Purine Club !
📅 30 juin à 14h au 1er juillet à 12h
📍 ESPCI, 10 rue Vauquelin, 75005 Paris
🔗 docs.google.com/forms/d/e/1F...
💡 Pensez aussi à votre cotisation annuelle
➡️ bit.ly/4hOcar6
Nous espérons vous y voir nombreux !
A clinician viewpoint on the 2024 European guidelines on the management of patients with atrial fibrillation
by L Fauchier UMR1327 and @chrudetours.bsky.social, JC Deharo @aphm-chu-marseille.bsky.social, F Sacher @chu-bordeaux.fr and A Cohen @ap-hp.bsky.social
www.sciencedirect.com/science/arti...
Evaluation of efficacy and safety of rituximab in patients with progressive interstitial lung disease with inflammatory component (EvER-ILD2): A multicentre double-blind placebo-controlled randomized trial
by M Ferreira, T Bejan-Angoulvant, S Marchand-Adam et al.
pubmed.ncbi.nlm.nih.gov/39693827/
P2 purinergic receptors at the heart of pathological left ventricular remodeling following acute myocardial infarction
a review by AV Vinhais da Silva, S Chesseron, O Benouna, J Rollin, S Roger, T Bourguignon, S Chadet and F Ivanes
Am J Physiol Heart Circ Physiol
pubmed.ncbi.nlm.nih.gov/39884315/
